V Tv Therapeutics Inc. - Understand $vtvt stock

$VTVT Market Cap: $52.76 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.000M

TTM

Gross Margin

Net Earnings

-$18.31M

TTM

Current Assets

$42.96M

Q3 2024

Current Liabilities

$6.424M

Q3 2024

Current Ratio

668.71%

Q3 2024

Total Assets

$43.16M

Q3 2024

Total Liabilities

$25.25M

Q3 2024

Book Value

$17.91M

Q3 2024

Cash

$41.60M

Q3 2024

P/E

-2.882

Nov 29, 2024 EST

Free Cash Flow

-$2.914M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$0.00	$2.018M	$4.005M	$6.410M	$2.764M	$12.43M	$291.0K	$634.0K	$519.0K	$1.549M	$980.0K
YoY Change	-100.0%	-49.61%	-37.52%	131.91%	-77.77%	4172.85%	-54.1%	22.16%	-66.49%	58.06%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$0.00	$2.018M	$4.005M	$6.410M	$2.764M	$12.43M	$291.0K	$634.0K	$519.0K	$1.549M	$980.0K
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$11.91M	$12.20M	$11.44M	$7.250M	$8.540M	$9.220M	$11.33M	$9.910M	$9.080M	$11.72M	$11.38M
YoY Change	-2.41%	6.62%	57.83%	-15.11%	-7.38%	-18.62%	14.33%	9.14%	-22.53%	2.99%
% of Gross Profit
Research & Development	$13.60M	$12.36M	$12.62M	$11.02M	$15.12M	$23.04M	$39.64M	$44.95M	$27.24M	$17.38M	$25.43M
YoY Change	10.02%	-2.12%	14.56%	-27.11%	-34.37%	-41.89%	-11.82%	65.04%	56.73%	-31.66%
% of Gross Profit
Depreciation & Amortization	$90.00K	$100.0K	$100.0K	$100.0K	$39.00K	$218.0K	$197.0K	$265.0K	$501.0K	$864.0K	$1.090M
YoY Change	-10.0%	0.0%	0.0%	156.41%	-82.11%	10.66%	-25.66%	-47.11%	-42.01%	-20.73%
% of Gross Profit
Operating Expenses	$25.50M	$24.56M	$24.07M	$18.27M	$23.66M	$32.26M	$50.97M	$55.65M	$38.66M	$30.45M	$36.81M
YoY Change	3.84%	2.04%	31.73%	-22.77%	-26.67%	-36.72%	-8.41%	43.95%	26.98%	-17.29%
Operating Profit	-$25.50M	-$22.54M	-$21.66M	-$11.85M	-$20.89M	-$19.82M	-$50.68M	-$55.02M	-$38.14M	-$28.90M
YoY Change	13.14%	4.05%	82.77%	-43.27%	5.39%	-60.89%	-7.88%	44.25%	31.99%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$459.0K	$15.00K	-$11.00K	-$680.0K	$1.827M	$3.290M	$3.092M	$398.0K	$108.0K	$286.0K	-$11.84M
YoY Change	2960.0%	-236.36%	-98.38%	-137.22%	-44.47%	6.4%	676.88%	268.52%	-62.24%	-102.42%
% of Operating Profit
Other Income/Expense, Net	-$923.0K	-$3.616M	$4.057M	-$270.0K	$1.000K	$46.00K	-$190.0K	-$22.00K	-$838.0K	-$503.0K	-$530.0K
YoY Change	-74.47%	-189.13%	-1602.59%	-27100.0%	-97.83%	-124.21%	763.64%	-97.37%	66.6%	-5.09%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$25.97M	-$24.87M	-$17.62M	-$12.80M	-$21.84M	-$23.65M	-$53.85M	-$55.35M	-$41.11M	-$36.10M	-$48.20M
YoY Change	4.39%	41.2%	37.63%	-41.39%	-7.64%	-56.09%	-2.72%	34.66%	13.87%	-25.1%
Income Tax	$0.00	$200.0K	$115.0K	$0.00	$100.0K	$200.0K	$800.0K	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.25M	-$19.16M	-$12.99M	-$8.499M	-$13.04M	-$7.911M	-$16.14M	-$16.35M	-$27.50M	-$36.10M	-$48.20M
YoY Change	5.67%	47.56%	52.81%	-34.84%	64.88%	-51.0%	-1.27%	-40.53%	-23.83%	-25.1%
Net Earnings / Revenue		-949.65%	-324.27%	-132.59%	-471.92%	-63.62%	-5547.77%	-2579.18%	-5298.27%	-2330.6%	-4918.37%
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.71	-$0.26	-$213.8K	-$180.3K	-$430.5K	-$635.3K	-$1.666M	-$1.712M	-$3.321M	-$1.100M	-$1.469M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$9.446M	$12.13M	$13.42M	$5.750M	$1.780M	$1.680M	$11.76M	$51.51M	$88.00M	$1.380M	$1.160M
YoY Change	-22.1%	-9.61%	133.3%	223.03%	5.95%	-85.71%	-77.17%	-41.47%	6276.81%	18.97%
Cash & Equivalents	$9.446M	$12.13M	$13.42M	$5.750M	$1.780M	$1.680M	$11.76M	$51.51M	$88.00M	$1.380M	$1.090M
Short-Term Investments										$0.00	$70.00K
Other Short-Term Assets	$1.109M	$2.552M	$2.149M	$1.310M	$1.060M	$1.790M	$600.0K	$610.0K	$1.110M	$230.0K	$1.050M
YoY Change	-56.54%	18.75%	64.05%	23.58%	-40.78%	198.33%	-1.64%	-45.05%	382.61%	-78.1%
Inventory
Prepaid Expenses
Receivables	$102.0K	$12.42M	$57.00K	$160.0K	$10.00K	$0.00	$8.000M	$0.00	$70.00K	$0.00	$220.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.66M	$27.09M	$15.62M	$7.220M	$2.840M	$3.470M	$20.36M	$52.12M	$89.19M	$1.610M	$2.420M
YoY Change	-60.67%	73.45%	116.36%	154.23%	-18.16%	-82.96%	-60.94%	-41.56%	5439.75%	-33.47%
Property, Plant & Equipment	$361.0K	$556.0K	$680.0K	$850.0K	$1.000M	$70.00K	$280.0K	$440.0K	$620.0K	$3.780M	$5.790M
YoY Change	-35.07%	-18.24%	-20.0%	-15.0%	1328.57%	-75.0%	-36.36%	-29.03%	-83.6%	-34.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$5.588M	$9.173M	$6.730M	$2.480M	$2.480M	$2.480M
YoY Change	-100.0%	-39.08%	36.3%	171.37%	0.0%	0.0%
Other Assets				$0.00	$2.940M	$2.540M	$4.790M	$1.930M	$1.670M	$110.0K	$110.0K
YoY Change				-100.0%	15.75%	-46.97%	148.19%	15.57%	1418.18%	0.0%
Total Long-Term Assets	$361.0K	$6.144M	$9.853M	$7.570M	$6.430M	$5.090M	$7.560M	$2.380M	$2.340M	$11.34M	$13.08M
YoY Change	-94.12%	-37.64%	30.16%	17.73%	26.33%	-32.67%	217.65%	1.71%	-79.37%	-13.3%
Total Assets	$11.02M	$33.24M	$25.47M	$14.79M	$9.270M	$8.560M	$27.92M	$54.50M	$91.53M	$12.95M	$15.50M
YoY Change
Accounts Payable	$4.075M	$2.461M	$1.876M	$1.930M	$2.230M	$2.900M	$2.270M	$3.060M	$3.260M	$2.660M	$4.840M
YoY Change	65.58%	31.18%	-2.8%	-13.45%	-23.1%	27.75%	-25.82%	-6.13%	22.56%	-45.04%
Accrued Expenses	$6.336M	$5.006M	$6.331M	$4.350M	$4.950M	$4.800M	$11.63M	$8.350M	$3.370M	$2.170M	$1.840M
YoY Change	26.57%	-20.93%	45.54%	-12.12%	3.13%	-58.73%	39.28%	147.77%	55.3%	17.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$80.76M
YoY Change										-100.0%
Long-Term Debt Due	$191.0K	$224.0K	$256.0K	$80.00K	$6.170M	$9.380M	$4.270M		$0.00	$160.0K	$150.0K
YoY Change	-14.73%	-12.5%	220.0%	-98.7%	-34.22%	119.67%			-100.0%	6.67%
Total Short-Term Liabilities	$10.62M	$7.708M	$8.498M	$6.390M	$13.38M	$18.84M	$26.93M	$11.43M	$7.730M	$6.860M	$87.58M
YoY Change	37.77%	-9.3%	32.99%	-52.24%	-28.98%	-30.04%	135.61%	47.87%	12.68%	-92.17%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$6.330M	$15.32M	$11.06M	$0.00	$36.01M	$2.270M
YoY Change					-100.0%	-58.68%	38.52%		-100.0%	1486.34%
Other Long-Term Liabilities	$18.95M	$19.69M	$1.754M	$4.610M	$4.730M	$3.760M	$5.280M	$430.0K	$250.0K	$30.79M	$20.00K
YoY Change	-3.77%	1022.63%	-61.95%	-2.54%	25.8%	-28.79%	1127.91%	72.0%	-99.19%	153850.0%
Total Long-Term Liabilities	$18.95M	$19.69M	$1.754M	$4.610M	$4.730M	$10.09M	$20.60M	$11.49M	$250.0K	$66.80M	$2.290M
YoY Change	-3.77%	1022.63%	-61.95%	-2.54%	-53.12%	-51.02%	79.29%	4496.0%	-99.63%	2817.03%
Total Liabilities	$35.70M	$43.98M	$35.21M	$94.89M	$58.29M	$91.41M	$179.0M	$145.4M	$169.5M	$73.67M	$89.87M
YoY Change	-18.83%	24.89%	-62.89%	62.79%	-36.23%	-48.92%	23.05%	-14.19%	130.08%	-18.03%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $52.756 Million

About vTv Therapeutics Inc.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 16 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Industry: Pharmaceutical Preparations Peers: BIORA THERAPEUTICS, INC. ELUTIA INC. Candel Therapeutics, Inc. CytomX Therapeutics, Inc. Decibel Therapeutics, Inc. GALECTIN THERAPEUTICS INC IMMUNIC, INC. Oncocyte Corp